Assembly Biosciences, Inc. is a non-accelerated filer and smaller reporting company focused on therapeutic product candidates, primarily through a collaboration with Gilead Sciences. As of September 30, 2026, the company remains pre-revenue and unprofitable, relying on third-party CROs and collaborators for clinical development and manufacturing.
Assembly Biosciences reported Q3 2026 financial results and announced the receipt of a $75 million collaboration extension fee from Gilead Sciences, extending its cash runway into 2029. The company also exercised its option to share 40% of U.S. development costs and profits for the HSV helicase primase inhibitor program and initiated a Phase 2 study for ABI-6250 in chronic hepatitis delta virus.
Counterparty
Gilead Sciences, Inc.
“This quarter, we rapidly advanced our liver disease program by initiating the Phase 2 study of ABI-6250 in chronic hepatitis delta virus and preparing for our Phase 2 study in cholestatic liver diseases, which we expect to begin in the first quarter next year. Alongside that progress, we elected to share U.S. costs and profits for the HSV helicase primase inhibitor program under our collaboration with Gilead, a decision we believe represents a significant opportunity to build long-term value. With a strong financial position, we look forward to the continued expansion of our pipeline and advancement of the herpesvirus and liver disease programs through their respective Phase 2 studies.”
Jason Okazaki, chief executive officer and president of Assembly Bio